FOLDAmicus Therapeutics, Inc.

$5B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+103.9% YoY

Gross Profit

$30M88.1% margin

Operating Income

-$81M-238.7% margin

Net Income

-$120M-353.3% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+4.3%

Cash Flow

Operating Cash Flow

-$79M

Free Cash Flow

-$81M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$765M

Total Liabilities

$313M

Stockholders' Equity

$452M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$17M	+103.9%
Gross Profit	$30M	$14M	+113.0%
Operating Income	-$81M	-$56M	-44.7%
Net Income	-$120M	-$50M	-141.0%

Geographic Segments

Non-US

$25M73%

UNITED STATES

$9M27%

FOLD Q1 2019 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena